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http://dx.doi.org/10.1016/j.jfma.201Background/Purpose: Lymphoid-enhancing factor 1 (LEF1) is a transcription factor mediating
Wnt/b-catenin signaling. In this study, we analyzed the clinicopathologic significance of
LEF1 expression in oral squamous cell carcinoma (OSCC).
Methods: Expression levels of LEF1 in 135 cases of OSCC were determined by immunohisto-
chemistry. The results were correlated with clinicopathologic parameters and patient
outcome.
Results: LEF1 was only occasionally detected in basal and parabasal cells of nontumorous squa-
mous epithelium. Overexpression of LEF1 was observed in 33 of 135 OSCCs (24%). LEF1 was
more frequently expressed in moderately to poorly differentiated cancer (p Z 0.0035) and
was associated with lymphovascular invasion (pZ 0.0252). Overexpression of LEF1 was signif-
icantly associated with poor prognosis (pZ 0.0176, hazard ratioZ 1.96, 95% CIZ 1.02e3.75).
Multivariate analysis revealed LEF1expression and margin status to be the significant indepen-
dent predictors for overall survival.
Conclusion: Our study suggests LEF1 expression in OSCC may play an important role in tumor
progression and can be served as a predictor of poor prognosis for patients with OSCC.
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LEF1 in oral squamous cell carcinoma 935Introduction Materials and methodsOral squamous cell carcinoma (OSCC), the most common
malignant tumor of the head and neck region worldwide, is
characterized by aggressive growth, local invasion, and
cervical lymph node metastasis. It is one of the leading
causes of cancer-related deaths in India and South Asian
countries due to the habit of chewing areca nut (Areca
catechu) preparations.1,2 The main treatment of OSCC in-
cludes surgery and adjuvant therapy of radiotherapy or
chemoradiation.3,4 In many cases, the conventional prog-
nostic factors used in clinical practice remain unsatisfactory
and are unable to discriminate tumors of the same clinical
stage.5 Despite advances in therapeutic modalities, the
survival rate of OSCC patients has not improved significantly
over the past decades. The 5-year survival rate is about
50w55%.6e8 Therefore, biologic prognostic markers to pre-
dict the clinical outcome and response to adjuvant therapy
are important and are helpful in determining the regimens
and extensity of treatment in the beginning.
The Wnt/b-catenin pathway is an important pathway for
tumor growth and invasion.9 In the absence of Wnt signaling,
the protein level of b-catenin is tightly controlled by a
multiprotein complex that contains adenomatous polyposis
coli (APC), axin, and glycogen synthetase kinase-3 which
phosphorylates the N-terminal of b-catenin and targets it for
degradation by the proteasome system.10 Upon activation by
Wnt signaling, b-catenin accumulates in the cytoplasm and
translocates to the nuclei, where it associates withmembers
of the T-cell factor/lymphoid-enhancing factor (TCF/LEF)
family of transcription factors to turn on Wnt target genes.11
Mutations of APC or b-catenin are frequent events in several
types of cancer, including colorectal cancer, endometrial
cancer, and hepatocellular carcinoma.12e14
Another possible mechanism for modulating Wnt/b-cat-
enin signaling is by the variable use of the nuclear binding
partners of b-catenin, namely TCF4 and LEF1. These belong
to the high mobility group family, which regulates gene
expression by inducing structural alteration in the DNA
helix.15 TCF4 is the main binding partner of b-catenin in
mammary and gut epithelium and is essential for mainte-
nance of the crypt stem cells of gut.16 TCF4 knockout mice
showed depletion of stem cell components of the small
intestine and which were replaced by differentiated non-
dividing cells.17 By contrast, the expression of LEF1 is
restricted to T- and pre-B lymphocytes.18 LEF1 has been
reported to be expressed in colorectal cancer and breast
cancer.19,20 When overexpressed, LEF1 enhances tumor
invasion by inducing epithelial to mesenchymal transition
(EMT).21 Therefore, overexpression of LEF1 in cancer may
result in a shift of binding partner of b-catenin from TCF4 to
LEF1, which enables EMT and tumor invasion. The mecha-
nism of overexpression of LEF1 in cancer is still unknown.
LEF1 has been reported to be transcriptionally activated by
the b-catenin/TCF4 complex, and is thought to be an
amplifier of Wnt/b-catenin signaling.22
In this study, we showed that LEF1 is frequently over-
expressed in OSCC, indicating that overexpression of LEF1 is
another mechanism for activating the Wnt/b-catenin
pathway in OSCC. We also found, that expression of LEF1 is
a strong prognostic factor for patients with OSCC.Tumor samples
Paraffin-embedded specimens from 135 patients with pri-
mary OSCC were obtained from the Department of Pathol-
ogy, National Taiwan University Hospital. The patients
included 120 males and 15 females. Diagnosis of OSCC was
based on histological examination of hematoxylin and
eosin-stained tissue sections. All patients underwent sur-
gical excision of the lesions at the National Taiwan Uni-
versity Hospital from 1998 to 2001. Specimens were
collected from the resection operation. Thirty-two patients
received postoperative radiotherapy and 20 patients
received combined chemotherapy and radiotherapy. The
study was conducted according to the regulation of the
Research Ethics Committee of National Taiwan University
Hospital; the specimens were anonymous and analyzed in a
blinded manner.
Immunohistochemical analysis
Tissue sections (5 mm) were dewaxed and rehydrated. Anti-
gen retrieval was done by autoclaving the slides in Trilogy
solution (Cell Marque, Hot Springs, AR, USA) at 121 C for 10
minutes. After blocking with 3% H2O2 and 5% fetal bovine
serum, the slides were allowed to react with a rabbit mono-
clonal antibody against LEF1 (1:100, C12A5, Cell Signaling,
Bererly, MA, USA) at 4 C overnight. The slides were then
incubated with polymer-HRP reagent (Dako Cytomation,
Glostrup, Denmark). The peroxidase activity was visualized
with diaminobenzidine tetrahydroxychloride solution (DAB,
Dako Cytomation). The sections were counterstained with
hematoxylin. Expression of LEF1 was determined by two in-
dependent observers, by semiquantitatively assessing the
percentage of stained tumor cells. Because LEF1 is occa-
sionally expressed in the basal keratinocytes of nontumorous
squamous epithelium and the positive percentage is usually
between 1% and 5%, dark brown nuclear staining in >5% of
tumor cells was defined as positive and staining in <5% of
tumor cells was defined as negative. For negative controls,
we replacedtheprimaryantibodywith5% fetal bovine serum.
Lymphocytes in slides served as the internal positive control.
Microarray analysis
Microarray dataset GSE30784 was downloaded from the
NCBI GEO database (www.ncbi.nlm.nih.gov/geo). This
dataset included gene expression profiles from 167 OSCC
samples and 45 nontumorous oral mucosa samples. The
difference of LEF1 mRNA expression levels between OSCC
and nontumorous oral mucosa was analyzed by the Student
t test.
Statistical analysis
The data analyses were carried out using MedCalc (MedCalc
Software, Mariakerke, Belgium) software. The correlation
between LEF1 expression and clinicopathologic parameters
was evaluated by using the c2 test. Survival rates were
Figure 1 Immunohistochemical staining of lymphoid-enhancing factor 1 (LEF1). (A) LEF1 is only occasionally expressed in basal
and parabasal cells of nontumorous squamous epithelium; (B) an oral squamous cell carcinoma (OSCC) without LEF1 expression.
Lymphocytes serve as internal positive control; (C) an OSCC with LEF1 expression in the periphery of tumor nests; and (D) an OSCC
with diffuse nuclear staining of LEF1. (Original magnification of all figures: 200.)
936 M.-C. Su et al.calculated by using the Kaplan-Meier method, and the dif-
ference in survival curves was analyzed by using the log-
rank test. Two-tailed p <0.05 was considered statistically
significant.Results
Immunohistochemical staining was performed to deter-
mine the expression of LEF1 in OSCC and nontumorous
squamous epithelium of the oral cavity. The slides wereFigure 2 (A) Lymphoid-enhancing factor 1 (LEF1) mRNA levels
tumorous oral mucosa; (B) by contrast, the expression levels of T-c
mucosa. LEF1 and TCF4 mRNA expression levels of 167 OSCC sample
microarray dataset GSE30784. The difference of LEF1 mRNA expre
analyzed by the Student t test. Control Z nontumorous oral mucoreviewed by a pathologist (Y.M.J.) and an oral pathologist
(C.Y.L.). The concordant rate in interpreting the slides
was 97.8%. The three cases with disconcordant results
were reviewed and a consensus was reached. LEF1 was
occasionally expressed in basal and parabasal cells of
squamous epithelium (Fig. 1A). LEF1 protein was detec-
ted in the tumor cell nuclei in 33 of 135 OSCCs (24%) by
immunohistochemical staining. The LEF1 protein expres-
sion in OSCC varied considerably and showed a hetero-
geneous distribution ranging from diffuse positive (>66%
of tumor cells are positive; 3 cases), heterogeneous toare higher in oral squamous cell carcinoma (OSCC) than non-
ell factor-4 (TCF4) were similar in OSCC and nontumorous oral
s and 45 nontumorous oral mucosa samples were retrieved from
ssion levels between OSCC and nontumorous oral mucosa was
sa.
Table 1 Analysis of LEF1 protein expression in oral squa-
mous cell carcinoma and correlation with clinicopatholog-
ical parameters.
Clinicopathological
features
Total
cases
LEF1 expression p
Negative
n (%)
Positive
n (%)
Age
<50 81 65 16 0.1173
50 54 37 17
Sex
Male 120 90 30 0.9154
Female 15 12 3
Site
Tongue 85 66 19 0.6136
Buccal mucosa 25 19 6
Other 25 17 8
Differentiation
Well-differentiated 56 50 6 0.0035
Moderate to poorly
differentiated
79 52 27
Margin
Free 121 92 29 0.9593
Involved 14 10 4
Lymphovascular invasion
Negative 65 56 9 0.0252
Positive 48 32 16
Perineural invasion
Negative 80 62 18 0.8555
Positive 32 26 6
T stage
T1þT2 96 74 22 0.6693
T3þT4 39 28 11
Nodal status
N0 86 69 17 0.1424
N1-3 49 33 16
Tumor stage
I þ II 67 52 15 0.7251
III þ IV 68 50 18
Figure 3 Kaplan-Meier analysis of overall survival in 135
patients with oral squamous cell carcinoma (OSCC). Patients
with lymphoid-enhancing factor 1 (LEF1)-positive OSCC had a
significantly lower survival rate than those with LEF1-negative
OSCC.
Table 2 Univariate analysis of overall survival for clini-
copathological parameters and lymphoid-enhancing factor
1 (LEF1) expression.
Clinicopathological
features
Hazard
ratio
(HR)
95% CI for HR p
Lower Upper
Age (<50 yrs vs. 50 yrs) 1.06 0.61 1.84 0.8849
Sex (M vs. F) 1.00 0.43 2.35 0.9960
Site (tongue vs. other) 1.02 0.58 1.79 0.9558
Differentiation (well vs.
moderately to
poorly differentiate)
1.69 0.97 2.93 0.0729
Margin (free vs. involved) 2.43 0.89 6.67 0.0118
LEF expression
[(e) vs. (þ)]
1.96 1.02 3.75 0.0176
T stage (T1e2 vs. T3e4) 1.91 0.99 3.70 0.0237
Nodal status (N0 vs. N1e3) 1.82 1.01 3.30 0.0298
Tumor stage
(I þ II vs. III þ IV)
2.33 1.34 4.06 0.0025
CI Z confidence interval; F Z female; HR Z hazard ratio;
M Z male.
LEF1 in oral squamous cell carcinoma 937focal positive (33e66% of tumor cells are positive; 6
cases), to positive in a small amount of tumor cells
(5e33% of tumor cells are positive; 24 cases; Fig. 1Be1D).
In those with heterogeneous to focal LEF1 expression,
LEF1 was predominantly expressed at the peripheries of
tumor nests (Fig. 1C). To further confirm that LEF1 is
overexpressed in OSCC, we analyzed the microarray
dataset GSE30784 obtained from the NCBI GEO database.
As shown in Fig. 2A, LEF1 expression is significantly higher
in OSCC than nontumorous oral mucosa (p <0.0001). By
contrast, the expression levels of TCF4 were similar in
OSCC and nontumorous oral mucosa.
To elucidate the role of LEF1 in OSCC progression, we
correlated LEF1 protein expression with a variety of clini-
copathological features. As shown in Table 1, LEF1
expression was more frequently seen in moderately to
poorly differentiated cancer and was associated with lym-
phovascular invasion, but it did not correlate with age, sex,
tumor location, margin status, perineural invasion, T stage,
nodal status, and tumor stage.The follow-up data of 135 OSCC patients for up to 12
years were used to assess the value of LEF1 for predicting
patient survival in OSCC patients after surgical resection.
Kaplan-Meier survival analysis showed a significantly
reduced overall survival (p Z 0.0176, hazard ratio Z 1.96,
95% CI Z 1.02e3.75) in OSCC patients with overexpression
of LEF1 (Fig. 3). Univariate analysis showed that LEF1
expression, margin status, tumor differentiation, T stage,
lymph node metastasis, and overall stage were prognostic
factors for OSCC patients (Table 2). To identify indepen-
dent factors for predicting patient survival, we put these
Table 3 Multivariate analysis of overall survival for clinicopathological parameters and lymphoid-enhancing factor 1 (LEF1)
expression.
Clinicopathological features Hazard ratio 95% CI Coefficient SE Z-Statistic p
LEF expression (þ vs. e) 2.08 1.13e3.84 0.73 0.31 2.34 0.0195
T stage (T1e2 vs. T3-4) 0.87 0.53e2.05 e0.13 0.43 e0.31 0.7578
Nodal status (N0 vs. N1e3) 1.46 0.53e3.97 0.38 0.51 0.73 0.4636
Margin (involved vs. free) 2.62 1.23e5.55 0.96 0.38 2.50 0.0122
Differentiation (well vs. moderate/poor) 0.76 0.39e1.46 e0.28 0.34 e0.84 0.4031
Tumor stage (I þ II vs. III þ IV) 0.34 0.10e1.14 e0.11 0.62 e1.74 0.0818
CI Z confidence interval; SE Z standard error.
938 M.-C. Su et al.six factors in a multivariate analysis using Cox’s propor-
tional hazard models. As shown in Table 3, only LEF1
expression and margin status emerged as the significant
independent prognostic markers for OSCC.
Discussion
The Wnt/b-catenin pathway is frequently activated in
cancers. Mechanisms include mutation of APC, b-catenin,
and axin, and epigenetic inactivation of Wnt inhibitors,
among others.23 Mutations of b-catenin or APC are not
detected in OSCC, but abnormal cytoplasmic/nuclear
accumulation was observed in about 20% of OSCC.24 Acti-
vation of the Wnt/ b-catenin pathway enhances tumor
growth, invasion, and metastasis through binding to TCF/
LEF transcription factors to turn on downstream targets.25
Although the roles of abnormal cytoplasmic/nuclear
accumulation of b-catenin have been extensively studied,
few studies have been focused on the binding partners of b-
catenin, i.e., LEF1 and TCF4. Previous studies showed LEF1
is overexpressed in colorectal cancer, breast cancer, and
prostate cancer.19,20,26 LEF1 mediates metastasis in pul-
monary adenocarcinoma27 and also enhances growth and
invasion in prostate cancer.26 Recently, we found that
transcriptional activation of LEF1 is one of the mechanisms
for hepatocyte growth factor to enhance tumor invasion.28
We also found that LEF1 is overexpressed in multiple types
of cancer, including OSCC.28
In univariate analysis, LEF1 expression is more frequently
seen in moderately or poorly differentiated OSCC. In non-
tumorous tissue, LEF1 is only expressed in basal/parabasal
cells. These observations suggest that LEF1 is a marker of
poorly differentiated keratinocytes, and the expression of
LEF1 is lost after cell maturation. Activation of Wnt/b-cat-
enin is a hallmark of stem cells in many organs.29 It is likely
that overexpression of LEF1 maintains keratinocytes in a
stem cell-like state. EMT is an important step for tumor in-
vasion. Stem cell-like populations in cancer often show
features of EMT, which are regulated by the Wnt/b-catenin
signal.25 This may be the reason why LEF1 promotes tumor
invasion and its expression predicts poor patient prognosis.
The clinical significance of LEF1 expression in cancer is
still not identified. This is the first study revealing that LEF1
can be served as a biomarker for cancer. Kaplan-Meier sur-
vival analysis showed that LEF1 expression predicts poor
prognosis for OSCC patients. Furthermore, margin status and
LEF1 expression emerged as the only independent prognosticmarkers in a multivariate analysis, in comparison with the
known clinicopathological parameters, including tumor size,
lymph node status, and overall stage. This striking finding
suggests that LEF1 may be a useful biomarker for predicting
patient outcome and may help clinicians in deciding a ther-
apeutic plan. Overall tumor stage is the most important
prognostic factor for clinical management of cancer pa-
tients. However, we found that overall tumor stage is not an
independent prognostic factor for patients with OSCC if im-
munostaining of LEF1 is included for analysis. Because LEF1
expression is highly associated with tumor differentiation, it
is likely that some intrinsic molecular properties of cancer
have a greater impact on patient outcome than the anatomic
distribution of cancer cells. Based on clinical data, the his-
tological grade is included as a parameter for tumor staging
of esophageal cancer in the 7th version of the AJCC cancer
stainingmanual.30 It is likely that anatomic and nonanatomic
cancer characteristics should both taken into consideration
for better stratification and personalized therapy of OSCC
patients.
In this study, we were unable to include some important
pathologic (e.g., lymph node extracapsular extension, lym-
phovascular invasion) and treatment (e.g., extent of surgery,
application of adjuvant radiations) variables that could
affect a patient’s survival in the multivariate analysis,
because those data were missing for some patients. Further
studies using larger numbers of cases are needed to investi-
gate whether LEF1 expression is an independent marker of
poor survival after adjustment for other important patho-
logic and treatment variables in patients with OSCC.
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